Study Details

Back to Search Results

Safety and tolerability study of claudiximab in patients with advanced gastroesophageal cancer

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT00909025

Astellas Study ID

The unique identification code given by the study sponsor.

GM-IMAB-001

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Advanced/Metastatic Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 Years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

May 2009 - May 2010

Masking

None (Open Label)

Enrollment number

15

Clinical first-in-human single-dose escalation study evaluating the safety and tolerability of claudiximab (iMAB-362) in hospitalized patients with advanced gastroesophageal cancer. A multi-center, phase I, open-label, i.v. infusion study

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Safety and tolerability study of claudiximab in patients with advanced gastroesophageal cancer? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Johannes Gutenberg Universität, 1.Med Klinik und Poliklinik

Mainz, Germany, 55131

Universitätsklinikum Essen, Innere Klinik (Tumorforschung)

Essen, Germany, 45122

Universität Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)

Heidelberg, Germany, 69120

Klinikum Rechts-der-Isar, III.Medizinische Klinik und Poliklinik

München, Germany, 81674

Pauls Stradins University

Riga, Latvia, 1002

Piejuras Hospital

Liepaja, Latvia, 3401

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo